Sydney, Australia, 1 May 2024: Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, announces that Ms. Jennifer Chow has given notice of her resignation as Chief Executive Officer and Managing Director of the Company. It is expected that Ms. Chow will leave the Company on May 24, 2024. During her tenure since late 2020, Ms. Chow has built out the Company’s unique portfolio of novel cell therapy assets, advanced the pipeline from early-stage development to the clinic and managed the Company’s operations. Executive Chairman, Paul Hopper, said: “Jenn was instrumental in building the Company from a single technology business based on the City of Hope CLTX brain cancer program up until today, where we now have three platform technologies across multiple Phase 1A and Phase 1b clinical trials. The Board acknowledges the major contributions made by Jenn and wishes her well in all future endeavours.”
Chimeric will announce further changes to its executive team in the short term
2 Explanations:
Either a t/o coming and she had a conflict of interest or fall out with Hopper. The latter the most likely as more changes to come.
CHM Price at posting:
3.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)